Compare Neurocrine Biosciences Inc (NBIX) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Snowflake Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Snowflake Inc trades at $271.26 (market cap $95.09B). The key difference: Snowflake Inc is far larger — about 5.5× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.
| NBIX | SNOW | |
|---|---|---|
Market Cap | $17.40B | $95.09B |
Sector | Health | Technology |
52-Week High | $180.55 | $280.16 |
52-Week Low | $123.10 | $121.11 |
Enterprise Value | $16.49B | $94.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Snowflake (SNOW) trades at $271.73, up 1.05% with strong bullish technical signals and consistent earnings beats. The company shows robust revenue growth from $1.2B in 2022 to $3.63B in 2025, though profitability remains negative with a -23.79% net margin. Analyst sentiment is overwhelmingly positive with 80.77% buy ratings and a $299.91 consensus target, while recent news highlights AI Data Cloud expansion and enterprise adoption.
Snowflake presents a growth investment opportunity with accelerating AI platform adoption and 30% revenue targets, but faces execution risks in achieving profitability amid high valuation multiples. The stock's upside depends on converting revenue growth to positive earnings while navigating competitive cloud data market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
